Literature DB >> 16107907

Effect of hyperlipidemia on QT dispersion in patients without ischemic heart disease.

Zoltán Szabó1, Mariann Harangi, István Lörincz, Ildikó Seres, Evelin Katona, Zsolt Karányi, György Paragh.   

Abstract

BACKGROUND: Lipoproteins are known to exert direct and indirect effects on cardiovascular function, but their effects on ventricular repolarization have not yet been clearly elucidated.
OBJECTIVES: To assess the effect of hyperlipidemia on the longest QT interval (QTmax) of the 12-lead surface electrocardiogram (ECG) and on QT dispersion (QTd) in type IIb hyperlipidemic patients without myocardial ischemia, and to compare these patients with healthy control subjects.
METHODS: Ninety-six hyperlipidemic patients (44 men and 52 women; mean age 53+/-13 years) and 101 healthy control subjects (43 men and 58 women; mean age 46+/-16 years) were examined. Total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol (LDL-C), triglyceride, apolipoprotein (apo) A1, apo B, lipoprotein(a), QTmax and QTd were measured. According to heart rate, corrected QTmax and corrected QTd were also determined.
RESULTS: A significant difference was observed between the two groups of subjects with respect to serum cholesterol, LDL-C, triglyceride, apo B, QTmax, corrected QTmax, QTd and corrected QTd. A positive significant correlation was found between cholesterol, triglyceride, LDL-C and all of the studied ECG parameters, between high density lipoprotein cholesterol and QTmax, apo B and QTd, and between body mass index and all of the studied ECG markers.
CONCLUSIONS: Hyperlipidemia may have a direct effect on the studied ECG markers.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107907

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  7 in total

1.  Effect of experimental hyperlipidaemia on the electrocardiographic effects of repeated doses of halofantrine in rats.

Authors:  Jigar P Patel; Dion R Brocks
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based Casale Monferrato Study.

Authors:  Sara Giunti; Gabriella Gruden; Paolo Fornengo; Federica Barutta; Cristina Amione; Giuseppe Ghezzo; Paolo Cavallo-Perin; Graziella Bruno
Journal:  Diabetes Care       Date:  2012-02-01       Impact factor: 19.112

3.  The association of long-term glycaemic variability versus sustained chronic hyperglycaemia with heart rate-corrected QT interval in patients with type 2 diabetes.

Authors:  Jian-Bin Su; Xiao-Hua Yang; Xiu-Lin Zhang; Hong-Li Cai; Hai-Yan Huang; Li-Hua Zhao; Feng Xu; Tong Chen; Xing-Bo Cheng; Xue-Qin Wang; Yan Lu
Journal:  PLoS One       Date:  2017-08-28       Impact factor: 3.240

4.  Cirrhotic cardiomyopathy: is there any correlation between the stage of cardiac impairment and the severity of liver disease?

Authors:  Rania Hammami; Mouna Boudabbous; Jihen Jdidi; Fatma Trabelsi; Fakher Mroua; Rahma Kallel; Ali Amouri; Dorra Abid; Nabil Tahri; Leila Abid; Samir Kammoun
Journal:  Libyan J Med       Date:  2017-12       Impact factor: 1.657

5.  Assessment of Hypertension Using Clinical Electrocardiogram Features: A First-Ever Review.

Authors:  Kathleen Bird; Gabriel Chan; Huiqi Lu; Heloise Greeff; John Allen; Derek Abbott; Carlo Menon; Nigel H Lovell; Newton Howard; Wee-Shian Chan; Richard Ribon Fletcher; Aymen Alian; Rabab Ward; Mohamed Elgendi
Journal:  Front Med (Lausanne)       Date:  2020-12-04

6.  Effect of L- arginine on electrocardiographic changes induced by hypercholesterolemia and isoproterenol in rabbits.

Authors:  Pradeep Kumar; Manish Goyal; J L Agarwal
Journal:  Indian Pacing Electrophysiol J       Date:  2009-01-07

Review 7.  Handling of Ventricular Fibrillation in the Emergency Setting.

Authors:  Zoltán Szabó; Dóra Ujvárosy; Tamás Ötvös; Veronika Sebestyén; Péter P Nánási
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.